No progression of subclinical atherosclerosis in HIV-infected patients starting an initial regimen including tenofovir alafenamide/emtricitabine plus raltegravir, dolutegravir or elvitegravir/cobicistat during a two-year follow-up

.

Source: Infectious Diseases - January 25, 2020 Category: Infectious Diseases Authors: Leonardo Calza Marco Borderi Vincenzo Colangeli Aurora Borioni Simona Coladonato Bianca Granozzi Pierluigi Viale Source Type: research